Loading…
Anthem Biosciences (ANTHEM)₹958.15+1.68%Biotechnology
In the Jun 2026 quarter (consolidated), Anthem Biosciences reported sales of ₹419 Cr, down 22.5% from Jun 2025, and net profit of ₹120 Cr, down 11.7% year on year. For the year to Mar 2026, sales were ₹2,128 Cr and net profit ₹591 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 339 | 526 | 499 | 484 | 541 | 551 | 424 | 612 | 419 |
| Expenses | 219 | 331 | 339 | 289 | 350 | 333 | 267 | 345 | 269 |
| Operating Profit | 121 | 196 | 161 | 196 | 191 | 219 | 157 | 268 | 152 |
| OPM % | 36.0% | 37.0% | 32.0% | 40.0% | 35.0% | 40.0% | 37.0% | 44.0% | 36.0% |
| Other Income | 19.01 | 28.01 | 24.01 | 14.01 | 23.02 | 47.99 | 7.99 | 52.01 | 24.99 |
| Interest | 3.99 | 3.99 | 2.99 | 0.99 | 1.99 | 2.99 | 0.00 | 1.99 | 0.99 |
| Depreciation | 19.03 | 20.06 | 20.04 | 30.08 | 26.07 | 34.06 | 35.10 | 40.11 | 30.05 |
| Profit before tax | 118 | 201 | 162 | 179 | 187 | 231 | 130 | 279 | 146 |
| Tax % | 30.0% | 19.0% | 23.0% | 54.0% | 27.0% | 24.0% | 29.0% | 32.0% | 17.0% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −17.94 | 0.99 | 0.00 |
| Net Profit | 81.82 | 162 | 124 | 82.84 | 136 | 173 | 92.86 | 190 | 120 |
| EPS (Rs) | 1.48 | 2.91 | 2.23 | 1.49 | 2.43 | 3.10 | 1.66 | 3.39 | 2.14 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 634 | 1,105 | 1,233 | 1,059 | 1,422 | 1,848 | 2,128 | 2,005 |
| Expenses | 452 | 697 | 668 | 628 | 917 | 1,176 | 1,294 | 1,214 |
| Operating Profit | 182 | 409 | 567 | 433 | 508 | 674 | 837 | 795 |
| OPM % | 29.0% | 37.0% | 46.0% | 41.0% | 36.0% | 36.0% | 39.0% | 39.7% |
| Other Income | 20.99 | 37.02 | 49.06 | 139 | 63.01 | 85.01 | 131 | 133 |
| Interest | 19.95 | 16.95 | 9.97 | 8.97 | 9.97 | 10.98 | 6.98 | 5.97 |
| Depreciation | 62.13 | 62.14 | 58.18 | 64.19 | 82.15 | 89.25 | 134 | 139 |
| Profit before tax | 121 | 367 | 548 | 499 | 479 | 659 | 827 | 786 |
| Tax % | 23.0% | 26.0% | 26.0% | 23.0% | 23.0% | 31.0% | 28.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 40.90 | 0.00 | 0.00 | −15.97 | −16.95 |
| Net Profit | 92.87 | 271 | 405 | 384 | 366 | 450 | 591 | 575 |
| EPS (Rs) | 110.74 | 319.99 | 462.51 | 6.76 | 6.58 | 8.08 | 10.56 | 10.29 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 19.0% | — |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 8.00 | 8.00 | 9.00 | 114 | 112 | 112 | 112 |
| Reserves | 413 | 692 | 1,346 | 1,627 | 1,812 | 2,299 | 2,929 |
| Borrowings | 159 | 99.91 | 35.00 | 126 | 239 | 113 | 54.01 |
| Other Liabilities | 208 | 233 | 229 | 149 | 236 | 285 | 335 |
| Total Liabilities | 788 | 1,034 | 1,620 | 2,015 | 2,399 | 2,810 | 3,429 |
| Fixed Assets | 305 | 360 | 328 | 448 | 482 | 704 | 781 |
| CWIP | 49.82 | 18.95 | 153 | 164 | 344 | 296 | 263 |
| Investments | 98.75 | 208 | 272 | 498 | 470 | 432 | 1,004 |
| Other Assets | 334 | 447 | 866 | 905 | 1,104 | 1,378 | 1,380 |
| Inventories | 125 | 35.16 | 58.22 | 129 | 212 | 341 | 126 |
| Trade receivables | 105 | 255 | 325 | 273 | 489 | 449 | 589 |
| Cash & equivalents | 21.95 | 40.89 | 348 | 342 | 184 | 171 | 274 |
| Total Assets | 788 | 1,034 | 1,620 | 2,015 | 2,399 | 2,810 | 3,429 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | 167 | 279 | 334 | 307 | 141 | 272 | 847 |
| Cash from investing activity | −109 | −195 | −204 | −374 | −220 | −147 | −700 |
| Cash from financing activity | −47.96 | −62.92 | 181 | 63.96 | −76.87 | −136 | −39.96 |
| Net cash flow | 8.99 | 18.01 | 308 | −5.99 | −158 | −11.99 | 103 |
| Capex | 47.20 | 121 | 26.10 | 185 | 118 | 262 | 212 |
| Free cash flow | 119 | 159 | 308 | 112 | −156 | 12.02 | 638 |
| CFO / OP % | 116.0% | 85.0% | 81.0% | 98.0% | 51.0% | 64.0% | 126.0% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor days | 61 | 84 | 97 | 95 | 126 | 89 | 101 |
| Inventory days | 186 | 29 | 52 | 139 | 129 | 167 | 56 |
| Days payable | 87 | 50 | 50 | 77 | 61 | 54 | 34 |
| Cash conversion cycle | 159 | 62 | 98 | 155 | 192 | 201 | 123 |
| Working capital days | 20 | 27 | 75 | 112 | 128 | 134 | 92 |
| ROCE % | — | 55.0% | 51.0% | 28.0% | 24.0% | 28.0% | 30.0% |
For the Jun 2026 quarter, Anthem Biosciences reported sales of ₹419 Cr, down 22.5% year on year and net profit of ₹120 Cr, down 11.7% year on year. The operating margin was 36.0%.
Anthem Biosciences' sales for the year to Mar 2026 were ₹2,128 Cr; over the last twelve months they were ₹2,005 Cr.
Net profit for the year to Mar 2026 was ₹591 Cr, and ₹575 Cr over the last twelve months. Earnings per share over the same trailing period were ₹10.29.
Anthem Biosciences reported borrowings of ₹54.01 Cr at Mar 2026, against cash and equivalents of ₹274 Cr.
Cash from operations was ₹847 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹638 Cr.